MilliporeSigma

Jerry Keybl, Ph.D., Head of Cell and Gene Therapy
Burlington, MA
(NYSE: MRK)
Cell and gene therapies hold the promise to change lives. Even as the path to patients accelerates, manufacturing and regulatory complexity remains. From solving your unique upstream and downstream challenges to meeting urgent manufacturing timelines and navigating uncertain regulatory guidelines, a knowledgeable partner can help move your cell and gene therapy from hype to hope. At MilliporeSigma, we give shape to cell and gene therapy development every day. With 30+ years of expertise, a global organization to integrate leading manufacturing technologies with process development, scale-up, safety testing, and regulatory experience, we can meet your therapy’s needs. We have more experience in this area than almost anyone else in the industry. We were the first gene therapy CDMO to produce a commercial product following a successful regulatory inspection. Our products and services include optimized manufacturing platforms, media, and reagents; manufacturing, biosafety, and characterization testing, as well as process development services. www.milliporesigma.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions